Atlas Trials

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Clinical trial NCT01047319 · TERMINATED

Trial details

NCT number
NCT01047319
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsing Multiple Sclerosis
Start date
2010-05-27
Primary completion
2017-06-30
Enrollment
1047

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.